Novogene(SH:688315) Ge Long Hui A P P·2026-02-26 10:55Core Viewpoint - The company reported a total operating revenue of 2.21 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 4.66%, despite a decline in net profit attributable to shareholders [1] Financial Performance - The net profit attributable to shareholders was 166 million yuan, representing a year-on-year decrease of 15.59% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 128 million yuan, down 24.75% year-on-year [1] - Total assets at the end of the reporting period reached 3.98 billion yuan, an increase of 9.50% compared to the end of 2024 [1] - Shareholders' equity attributable to the parent company was 2.65 billion yuan, up 6.33% from the end of 2024 [1] Strategic Initiatives - The company is actively responding to macroeconomic challenges and fluctuations in client funding, managing to achieve stable revenue growth [1] - To seize long-term market opportunities, the company is significantly increasing its R&D investment, focusing on AI-enabled research, single-cell and spatial multi-omics, protein and metabolomics solutions, and clinical translation [1]